Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis
Open Access
- 4 May 2004
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 140 (9) , 689-699
Abstract
No randomized, controlled trial of screening for diabetes has been conducted. In the absence of direct evidence, cost-effectiveness models may provide guidance about preferred screening strategies. To estimate the incremental cost-effectiveness of 2 diabetes screening strategies: screening targeted to people with hypertension and universal screening. Markov model. United Kingdom Prospective Diabetes Study, Hypertension Optimal Treatment trial, and recent cost data. General primary care population in the United States. Lifetime. Health care system. Diabetes screening targeted to people with hypertension and universal screening. Cost per quality-adjusted life-year (QALY) gained. Costs (in 1997 U.S. dollars) and QALYs discounted at a 3% annual rate. At all ages, incremental cost-effectiveness ratios were more favorable for screening targeted to people with hypertension than for universal screening. For example, at age 55 years, the cost per QALY for targeted screening compared with no screening was $34 375, whereas the cost per QALY for universal screening compared with targeted screening was $360 966. Screening was more cost-effective for ages 55 to 75 years than for younger ages. In single-way and probabilistic sensitivity analyses, findings were robust to therapy costs, screening costs, screening lead time, reduced effectiveness of intensive antihypertensive therapy, and increased relative risk reduction for stroke attributable to intensive hypertension control. We did not consider screening targeted to persons with dyslipidemia, and we used studies of people whose diabetes was detected clinically to estimate screening benefits. Diabetes screening targeted to people with hypertension is more cost-effective than universal screening. The most cost-effective strategy is targeted screening at age 55 to 75 years.Keywords
This publication has 40 references indexed in Scilit:
- Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokesKidney International, 2002
- The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitusThe American Journal of Medicine, 2001
- Performance of Recommended Screening Tests for Undiagnosed Diabetes and DysglycemiaDiabetes Care, 2001
- Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteriaBMJ, 2001
- ESTIMATING THE MICROVASCULAR BENEFITS OF SCREENING FOR TYPE 2 DIABETES MELLITUSInternational Journal of Technology Assessment in Health Care, 2000
- The Progressive Cost of Complications in Type 2 Diabetes MellitusArchives of internal medicine (1960), 1999
- Screening for diabetes: what are we really doing?BMJ, 1998
- Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994Diabetes Care, 1998
- Estimated Benefits of Glycemic Control in Microvascular Complications in Type 2 DiabetesAnnals of Internal Medicine, 1997
- Screening for NIDDM in Nonpregnant Adults: A review of principles, screening tests, and recommendationsDiabetes Care, 1995